Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children. (3rd July 2017)

• Record Type: Journal Article
• Authors: Cohen, Stanley A.; Aloi, Marina; Arumugam, Ramalingam; Baker, Robert; Bax, Kevin; Kierkuś, Jaroslaw; Koletzko, Sibylle; Lionetti, Paolo; Persson, Tore; Eklund, Stefan
• Is Part Of: Current medical research and opinion. Volume 33:Number 7(2017)
• Page Start: 1261
• Page End: 1268
• Publication Date: 2017-07-03
• Subjects: Cortisol -- inflammatory bowel diseases -- pediatric Crohn's disease -- pituitary– adrenal system; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2017.1313213
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-moderate Crohn's disease (CD) in children. Methods: The consecutive, multicenter, open-label, non-comparative studies enrolled patients aged 6–17 years. In the induction study, patients with active CD of the ileum and/or ascending colon received budesonide 9 mg or 6 mg once daily for 8 weeks; in the maintenance study, patients in remission received budesonide 6 mg once daily for 12 weeks. The primary objective was assessment of safety, including glucocorticosteroid-related side effects and serum cortisol levels. Efficacy was assessed using the Pediatric Crohn's Disease Activity Index (PCDAI), and health-related quality of life (HRQoL) using the IMPACT-III questionnaire. Results: In the induction study ( n = 108), most adverse events were related to CD, commonly abdominal pain; possible glucocorticosteroid-related effects included acne and increased appetite but without significant weight gain. Subnormal morning cortisol levels were observed in 32 of 103 patients after 8 weeks. Budesonide reduced disease activity from baseline (mean ± standard deviation, 9.1 ± 8.5 vs. 19.1 ± 10.1, p < .001) with 58.1% of patients reaching remission (PCDAI <10); HRQoL improved ( p < .001). In the maintenance study ( n = 50), mean disease activity worsened ( p = .047) with HRQoL unchanged ( p = .33). Conclusions: Budesonide treatment was generally well tolerated, although the potential for adrenal suppression was noted. Budesonide was effective for induction of remission in children with mild-to-moderate CD but not for maintaining remission (ClinicalTrials.gov identifiers: NCT01444092, NCT01453946).